Siemens Healthineers AG (SHL) AI Stock Analysis

• Market Cap: €49.81B
• Dividend Yield: 2.15%
• Average Volume (3M): 1.38M
• Price to Earnings (P/E): 23.3
• Beta (1Y): 1.07
• Revenue Growth: 4.53%
• EPS Growth: 10.12%
• Country: DE
• Employees: 72,000
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Devices
• EPS (TTM): 0.68
• Shares Outstanding: 1,128,000,000
• 10 Day Avg. Volume: 1,257,893
• 30 Day Avg. Volume: 1,377,654
• PEG Ratio: 2.46
• Price to Book (P/B): 2.86
• Price to Sales (P/S): 2.20
• P/FCF Ratio: 22.75
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: €54.43
• Price Target Upside: 11.73% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 13
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 67 Neutral
• Price Target: €46.00 ▼(-5.58% Downside)

Siemens Healthineers AG's overall stock score reflects strong financial performance and positive earnings call guidance, tempered by technical analysis indicating bearish trends and moderate valuation metrics. The company's ability to navigate macroeconomic challenges will be crucial for future growth.

Positive Factors

Strong Segment Growth

The robust growth in key segments like Imaging and Varian indicates strong market demand and effective product positioning, supporting long-term revenue expansion.

Diagnostics Profitability Improvement

Improved profitability in Diagnostics through transformation efforts highlights operational efficiency and potential for sustained margin enhancement.

Healthy Global Demand

Broad-based global demand, particularly in the Americas and EMEA, underscores the company's strong competitive position and growth potential outside China.

Negative Factors

China Market Challenges

Persistent challenges in the Chinese market could hinder overall revenue growth, impacting strategic goals and regional performance.

Tariff and Foreign Exchange Headwinds

Tariff and currency headwinds pose risks to profitability, necessitating strategic adjustments to mitigate financial impacts.

Diagnostics Segment Pressure

Ongoing pressure in the Diagnostics segment from procurement issues in China may constrain revenue growth and require strategic focus.

Siemens Healthineers AG Business Overview & Revenue Model

Company Description

Siemens Healthineers AG, through its subsidiaries, develops, manufactures, and sells a range of diagnostic and therapeutic products and services to healthcare providers worldwide. The company operates through four segments: Imaging, Diagnostics, Varian, and Advanced Therapies. The Imaging segment provides magnetic resonance imaging, computed tomography, X-ray systems, molecular imaging, and ultrasound systems. The Diagnostics segment offers in-vitro diagnostic products and services to healthcare providers in laboratory, molecular and point-of-care diagnostics; and workflow solutions for laboratories and informatics products. The Varian segment provides cancer care technologies, and solutions and services to oncology departments in hospitals and clinics; and technology-enabled optimized workflows, clinical services and consulting capabilities, and digital solutions and applications for managing treatment and therapy. The Advanced Therapies segment offers products that are designed to support image-guided minimally invasive treatments in various areas, such as cardiology, interventional radiology, and surgery; and angiography systems and mobile C-arms, including a robotic-assisted platform for endovascular coronary and peripheral vascular interventions. It also provides equipment performance management, clinical education and e-learning, asset management, and managed departmental services for laboratories and healthcare facilities, as well as consulting and digital health services. The company is headquartered in Erlangen, Germany. Siemens Healthineers AG operates as a subsidiary of Siemens Aktiengesellschaft.

How the Company Makes Money

Siemens Healthineers generates revenue through several key streams, primarily from the sale of medical imaging equipment, laboratory diagnostics products, and healthcare IT solutions. Their revenue model includes direct sales, service contracts, and ongoing maintenance agreements for their installed base of equipment. Additionally, the company benefits from partnerships with healthcare providers and institutions, which often involve long-term contracts for the supply of diagnostic and imaging technology. Other significant revenue sources include software solutions for healthcare management and digital health services, which are increasingly crucial as healthcare systems move towards more integrated and data-driven approaches. The company's investments in research and development also play a critical role in maintaining its competitive edge and driving sales growth through the introduction of innovative products and technologies.

Siemens Healthineers AG Financial Statement Overview

Summary

Siemens Healthineers AG demonstrates strong financial health with consistent profitability and efficient use of resources. However, recent revenue and cash flow trends show some concerns, which need addressing to maintain growth momentum.

Income Statement

Siemens Healthineers AG has shown consistent revenue growth over the years, although there was a slight decline in the most recent year. The company maintains strong gross and net profit margins, indicating efficient cost management and profitability. However, the recent dip in revenue growth rate and net profit margin suggests potential challenges in maintaining growth momentum.

Balance Sheet

The company's debt-to-equity ratio is relatively stable, indicating a balanced approach to leveraging. Return on equity is healthy, reflecting efficient use of equity to generate profits. However, the slight increase in debt levels over the years could pose a risk if not managed carefully.

Cash Flow

Operating cash flow and free cash flow have shown fluctuations, with recent declines in free cash flow growth. The operating cash flow to net income ratio is moderate, suggesting reasonable cash generation relative to net income. The company should focus on stabilizing cash flow to support future investments and operations.

Breakdown	TTM	Dec 2025	Dec 2025	Dec 2024	Dec 2023	Dec 2022
Income Statement
Total Revenue	23.38B	―	23.38B	22.36B	21.68B	21.71B
Gross Profit	9.03B	―	9.03B	8.47B	7.71B	8.14B
EBITDA	4.58B	―	4.58B	4.22B	3.78B	4.26B
Net Income	2.14B	―	2.14B	1.94B	1.51B	2.04B
Balance Sheet
Total Assets	44.37B	―	44.37B	46.05B	46.68B	49.06B
Cash, Cash Equivalents and Short-Term Investments	2.17B	―	2.17B	2.68B	1.64B	1.44B
Total Debt	15.06B	―	15.06B	16.21B	16.65B	16.65B
Total Liabilities	26.28B	―	26.28B	27.81B	28.55B	29.20B
Stockholders Equity	18.04B	―	18.04B	18.20B	18.08B	19.84B
Cash Flow
Free Cash Flow	2.27B	―	2.27B	1.77B	971.00M	1.40B
Operating Cash Flow	3.08B	―	3.08B	2.47B	1.81B	2.26B
Investing Cash Flow	-906.00M	―	-906.00M	-666.00M	-1.07B	-868.00M
Financing Cash Flow	-2.59B	―	-2.59B	-1.30B	-380.00M	-1.40B

Siemens Healthineers AG Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 48.72
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For DE:SHL, the sentiment is Neutral. The current price of 48.72 is above the 20-day moving average (MA) of 43.02, above the 50-day MA of 45.16, and above the 200-day MA of 46.80, indicating a neutral trend. The MACD of -0.08 indicates Negative momentum. The RSI at 56.69 is Neutral, neither overbought nor oversold. The STOCH value of 86.03 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for DE:SHL.

Siemens Healthineers AG Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
MRK	76 Outperform	€51.89B	17.55	10.32%	1.84%	1.47%	9.64%
SHL	67 Neutral	€49.81B	23.32	11.45%	2.15%	4.53%	10.12%
AFX	66 Neutral	€3.58B	24.80	6.79%	1.50%	7.82%	-19.80%
FME	64 Neutral	€11.71B	16.43	5.41%	3.57%	2.10%	9.19%
SRT	64 Neutral	€14.54B	95.22	5.01%	0.40%	5.82%	59.90%
FRE	62 Neutral	€26.64B	23.54	7.50%	2.09%	0.63%	―
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

Siemens Healthineers AG Corporate Events

Siemens Healthineers Reports Strong Q3 2025 Earnings Amid Challenges

Siemens Healthineers’ recent earnings call painted a picture of robust performance, with the company achieving notable growth across key segments. The sentiment was largely positive, driven by successful initiatives such as Value Partnerships and a transformative approach in Diagnostics. However, challenges such as tariff and foreign exchange headwinds, coupled with difficulties in the Chinese market, were highlighted as potential concerns for upcoming quarters.

Siemens Healthineers Reports Strong Q3 2025 Growth

Siemens Healthineers is a leading global medical technology company specializing in imaging, diagnostics, and advanced therapies, with a focus on healthcare innovations that improve patient outcomes worldwide.